Calcium-channel antagonists in cardiovascular disease.
In the last 2 years there has been considerable controversy over the safety of certain calcium antagonists. This article discusses recent drug developments, summarizes the publications that sparked the controversy, highlights results of the l latest trials of calcium antagonists and considers the range of clinical conditions in which calcium antagonists may play a useful role.
Holdright
D R
DR
Department of Cardiology, Middlesex Hospital, London.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D004110:Diltiazem / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D009543:Nifedipine / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D014700:Verapamil / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D014700:Verapamil; D004110:Diltiazem; D009543:Nifedipine